期刊文献+

穿琥宁对原发性血小板增多症患者巨核细胞体外扩增的影响 被引量:1

Effect of Chuan-Huning on Amplification of Megakaryocytes in Patients With Essential Thrombocytosis in Vitro
下载PDF
导出
摘要 目的:研究穿琥宁注射液对原发性血小板增多症患者巨核细胞体外扩增的影响。方法:采集12例原发性血小板增多症患者骨髓及血小板计数正常的缺铁性贫血患者骨髓,分离出CD34+细胞,接种于IMEM悬浮培养体系中,试验组及对照组加入TPO、IL-1β、IL-3、IL-6、Fit-3L和不同浓度剂量的穿琥宁注射液,分别在3、7、10、14d收集培养扩增的细胞,通过流式细胞术检测巨核细胞表型及数量,血浆块法检测巨核细胞集落形成单位(CFU-MK)数。结果:试验组巨核细胞扩增倍数及CFU-MK的形成能力随着穿琥宁剂量的递增逐渐减弱,呈明显量效关系,并明显弱于未加穿琥宁组及对照组;对照组未呈现量效关系。巨核细胞在7~10d扩增速度最快,14d时减慢。巨核祖细胞(CD34+CD41+细胞)在7d时最多,在10~14d时下降。结论:穿琥宁对原发性血小板增多症患者骨髓中巨核细胞增殖有抑制作用。 Objective: To study the effect of Chuan-Huning on amplificatin of megakaryocytes in patients with essential thrombocytosis (ET) in vitro. Methods: CD34^+ fraction were collected from bone marrow cells of 12 essential thrombocytosis patients and 12 iron deficiency anemic patients with normal blood platelets count and cultured in IMEM media supplemented with TPO, IL-1β,IL-3, IL-6 and Fit-3L. Different concentrations of purified Chuan-Huning solution were added into liquid culture while the same volume of saline served as control. Suspension cells were harvested after 3, 7, 10 and 14 days incubation respectively and examined for megakaryocyte marker by flow cytometry and megakaryocytic colony-forming unit (CFU-MK). Results: The number of megakaryocytes and the CFU-MK in ET group were greatly inhibited by Chuan-Huning compared to control group. This effect was most significant following 14 days of culture and was dose dependent. The megakaryocytic progenitor cells (CD34^+ CD41^+ ) were amplified following 7 days culture but reduced after 10 to 14 days culture. Conclusions:Chuan-Huning inhibits proliferation of megakaryocytic progenitor cells in essential thrombocytosis.
出处 《内科急危重症杂志》 2008年第3期151-153,共3页 Journal of Critical Care In Internal Medicine
关键词 穿琥宁 原发性血小板增多症 巨核细胞扩增 Chuan-Huning Essential thrombocytosis Megakaryocyte Amplification
  • 相关文献

参考文献5

二级参考文献9

  • 1范淑惠,许建秦.穿琥宁注射液的临床应用[J].陕西中医,1994,15(11):526-527. 被引量:37
  • 2袁孝莉,张玉华.穿琥宁过敏2例报告[J].四川中医,1997,15(2):25-25. 被引量:5
  • 3Wolanskyj AP,Lasho TL,Schwager SM,et al.JAK2 mutation in essential thrombocythaemia:clinical associations and long-term prognostic relevance.Br J Haematol,2005,131:208-213. 被引量:1
  • 4Baxter EJ,Scott LM,Campbell PJ,et al.Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders.Lancet,2005,365:1054-1061. 被引量:1
  • 5Kralovics R,Passamonti F,Buser AS,et al.A gain-of-function mutation of JAK2 in myeloproliferative disorders.N Engl J Med,2005,352:1779-1790. 被引量:1
  • 6Levine RL,Wadleigh M,Cool J,et al.Activating mutation in the tyrosine kinase JAK2 in polycythemia vera,essential thrombocythemia,and myeloid metaplasia with myelofibrosis.Cancer Cell,2005,7:387-397. 被引量:1
  • 7Lee JW,Kim YG,Soung YH,et al.The JAK2 V617F mutation in de novo acute myelogenous leukemias.Oncogene,2006,25:1434-1436. 被引量:1
  • 8Levine RL,Loriaux M,Huntly BJ,et al.The JAK2V617F activating mutation occurs in chronic myelomonocytic leukemia and acute myeloid leukemia,but not in acute lymphoblastic leukemia or chronic lymphocytic leukemia.Blood,2005,106:3377-3379. 被引量:1
  • 9王丽,刘宏伟,宋铁,任彦辉.穿琥宁针剂的研究与临床应用[J].中医药信息,1998,15(1):9-10. 被引量:33

共引文献66

同被引文献6

二级引证文献6

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部